Despite inevitable changes, including introduction to new materials and innovations will continue, its primary role as a protective agent remains paramount.
March 9, 2022
The pharmaceutical industry is undergoing a tremendous packaging revolution, paving way for the future development of intelligent solutions. One such breakthrough achieved in this space is the blister packaging.
Blister Packaging for Certain Immediate Release Opioid Analgesics for Treatment of Acute Pain – Docket No. FDA-2019-N-1845 as it relates to opioid packaging, and recently passed Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients (SUPPORT) Act, passed in late 2018.
There are a wide range of solutions that can be used to increase the shelf life of capsules, tablets, pills and other pharma products. Among these are PVC, PCTFE, PVDC and thermoform blisters for less sensitive products or Alu-Alu cold form blisters for APIs that are more sensitive.
Maruho Hatsujyo Innovations has introduced the EAGLE-Omni blister machine, which performs forming, sealing and punching operations at sequential stations.
Anyone associated with pharmaceuticals and packaging is likely aware President Trump signed the SUPPORT Act recently. The Substance Use–Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act, also known as SUPPORT for Patients and Communities Act, includes a specific address to the type of packaging that should be utilized to stem the tide on opioid addiction.
While the U.S. consumer is accustomed to seeing medication in both bottles and blister packs, bottles remain the dominant format in the U.S. Alternatively, since the end of World War II, the European standard for packaging medication has shifted toward the use of blister packs.